CDKN3 expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma .

Objective: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide. This study investigated the relationship between cyclin-dependent kinase inhibitor (CDKN)3 and prognosis and pathological characteristics in HCC patients to determine whether it could be used as a prognostic factor and/or therapeutic target for HCC drug development.

Methods: We previously showed that CDKN3 is deregulated in HCC tumor samples.